share_log

藥明生物：截至二零二四年六月三十日止六個月之中期業績公告

WUXI BIO: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024

HKEX ·  Aug 21 20:00

Summary by Moomoo AI

藥明生物公布2024年上半年業績，收益輕微增長1.0%至人民幣8,574.2百萬元，毛利率下降2.8個百分點至39.1%，純利大幅下滑23.9%至人民幣1,780.3百萬元。公司擁有人應佔純利更是下降33.9%至人民幣1,499.1百萬元。儘管面臨挑戰，藥明生物保持穩健業務發展，項目數增長顯著，綜合項目總數增至742個。董事會決定不派發中期股息。展望未來，藥明生物將繼續投資提升能力及規模，以支持持續增長。
藥明生物公布2024年上半年業績，收益輕微增長1.0%至人民幣8,574.2百萬元，毛利率下降2.8個百分點至39.1%，純利大幅下滑23.9%至人民幣1,780.3百萬元。公司擁有人應佔純利更是下降33.9%至人民幣1,499.1百萬元。儘管面臨挑戰，藥明生物保持穩健業務發展，項目數增長顯著，綜合項目總數增至742個。董事會決定不派發中期股息。展望未來，藥明生物將繼續投資提升能力及規模，以支持持續增長。
Wuxi Bio released its performance for the first half of 2024, with a slight increase in revenue of 1.0% to RMB 8,574.2 million, and a decrease in gross margin of 2.8 percentage points to 39.1%. Net profit also saw a significant decline of 23.9% to RMB 1,780.3 million. The attributable net profit of the company's owners also decreased by 33.9% to RMB 1,499.1 million. Despite the challenges, Wuxi Bio maintained steady business development, with a significant increase in the number of projects, reaching a total of 742. The board of directors decided not to distribute interim dividends. Looking ahead, Wuxi Bio will continue to invest in enhancing its capabilities and scale to support sustained growth.
Wuxi Bio released its performance for the first half of 2024, with a slight increase in revenue of 1.0% to RMB 8,574.2 million, and a decrease in gross margin of 2.8 percentage points to 39.1%. Net profit also saw a significant decline of 23.9% to RMB 1,780.3 million. The attributable net profit of the company's owners also decreased by 33.9% to RMB 1,499.1 million. Despite the challenges, Wuxi Bio maintained steady business development, with a significant increase in the number of projects, reaching a total of 742. The board of directors decided not to distribute interim dividends. Looking ahead, Wuxi Bio will continue to invest in enhancing its capabilities and scale to support sustained growth.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated